Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject for Anemia in Cancer Patients
NCT02599012Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Sep 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ferric carboxymaltose in anemia, sponsored by Samsung Medical Center. Primary endpoint: Hemoglobin response. Status: unknown.
02
Drugs
ferric carboxymaltose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02599012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599012.